Medifocus Inc.  

(Public, CVE:MFS)   Watch this stock  
Find more results for MFS
0.0800
0.0000 (0.00%)
Oct 23 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.08 - 0.25
Open     -
Vol / Avg. 0.00/48,666.00
Mkt cap 9.37M
P/E     -
Div/yield     -
EPS -0.06
Shares 117.26M
Beta 0.31
Inst. own     -

Key stats and ratios

Q2 (Jun '14) 2014
Net profit margin -72.63% -113.94%
Operating margin -72.09% -97.00%
EBITD margin - -83.09%
Return on average assets -73.96% -91.09%
Return on average equity - -340.93%
CDP Score - -

Address

The Exchange Tower Suite 1800, 130 King Street West, PO Box 427
BURLINGTON, ON M5X 1E3
Canada
+1-905-3197070 (Phone)
+1-905-5176060 (Fax)

Website links

Description

Medifocus Inc. develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostatic Hyperplasia (BPH). The Company owns two technology platforms with United States and international patent protection: The Endo-thermotherapy Platform-a catheter-basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites, and The Adaptive Phased Array Microwave Focusing Platform-invented by MIT and licensed to Medifocus, directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company�s APA 1000 Breast Cancer Treatment System, developed from the APA technology platform, is in pivotal Phase-III clinical trials.

Officers and directors

Grant B. Walsh Chairman of the Board
Yim-Pan Cheung Ph.D. President, Chief Executive Officer, Director
Mirsad Jakubovic Chief Financial Officer
John Mon Chief Operating Officer
Shuen Chuen Chan Independent Director
Age: 64
Augustine Pok Yu Chow Independent Director
Ernest Eves QC Independent Director
Age: 68
Tak Cheung Yam Independent Director
Age: 51